Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Steris's Capital Expenditure for the
three
months ended in Dec. 2024 was $-89.23 Mil. Its Revenue for the
three
months ended in Dec. 2024 was $1,370.57 Mil.
Hence, Steris's Capex-to-Revenue for the
three
months ended in Dec. 2024 was 0.07.
Steris Capex-to-Revenue Historical Data
The historical data trend for Steris's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Steris's Capex-to-Revenue
For the Medical Devices subindustry, Steris's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Steris's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Steris's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Steris's Capex-to-Revenue falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Steris (NYSE:STE) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Steris Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of Steris's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STE has been successfully added to your 